Biology subjects

Nedumaran, P.

Publications and source records attributed to Nedumaran, P..

3 recordsLinked to original sources

bioRxiv2026

IL-17RC signaling connects intestinal microbiota and neuroimmune interactions in atherosclerosis

While dysbiosis and inflammation were previously implicated in cardiovascular diseases, the circuits of how microbiota drives distant perivascular innervation, neuroinflammation and atherosclerosis remains unknown. Here, we report that IL-17RC signaling in intestine protects from atherosclerosis controlling intestinal barrier and microbiota, and loss of IL-17RC in intestinal epithelial cells alters microbiota, enhances perivascular innervation and aortic inflammation, augmenting the disease. Neuronal outgrowth is functionally dependent on microbiota and is essential for neuroinflammation and augmentation of atherosclerosis as chemical denervation reduces inflammation, macrophage activation and disease progression. Microbiota-dependent IL-17A producing {gamma}{delta} T cells accumulate in aorta to promote neuronal outgrowth and activation that can be reversed by {gamma}{delta} T cell blockade. Perivascular neuron activation is further dependent on cell autonomous IL-17 signaling as IL-17RC ablation in sympathetic neurons protected mice from microbiota-driven atherosclerosis. Together, our data illuminate how intestinal cytokine signaling distantly restrains neuroimmune interactions in aorta and uncovers a novel link between IL-17 signaling, microbiota, perivascular innervation and neuroimmune pro-inflammatory crosstalk instrumental for atherosclerosis progression. SummaryIL-17RC signaling regulates intestinal dysbiosis and perivascular neuronal outgrowth that modulates inflammation in atherosclerosis.

immunology↗

bioRxiv2026

Asporin Improves Cardiac Myocyte Response to Ischemia and Reperfusion Stress

BackgroundMyocardial Infarction (MI) remains a leading cause of mortality worldwide, despite advancements in clinical therapies and interventions. MI results from prolonged ischemia, leading to hypoxia-induced damage to cardiac tissue and reperfusion-injury (R/I) that aggravates cardiomyocyte (CM) loss. One key cellular event during this process is accumulation of dysfunctional mitochondria, resulting from environmental hypoxia and subsequent oxidative stress upon reperfusion. Post-MI cardiac-remodeling involves changes in both cellular and extracellular matrix (ECM). Ubiquitin-dependent and independent autophagy are crucial for cardio protection during this phase. The ECM provides structural integrity and functions as a reservoir for signaling molecules. Asporin (ASPN), a small leucine-rich proteoglycan, plays a role in modulating cardiac-remodeling by limiting excessive fibrosis and protecting CMs from cell death. MethodsWe investigated the therapeutic potential of ASPN by using an exogenous recombinant peptide of ASPN (rASPN), testing its effects using an in-vitro ischemia-reperfusion (I/R) model simulating MI conditions. Two I/R models were developed using an immortalized human embryonic cardiac cell line to reflect the hypoxia-reperfusion (H/R) phases of MI. In the No-Reoxygenation (No-ReOx) model, cells were subjected to hypoxia for 18 hours, with or without exogenous rASPN. In the Reoxygenation (ReOx) model, cells underwent 18 hours of hypoxia, then 12 hours of reoxygenation (simulating reperfusion), with or without rASPN. ResultsProteomics revealed that ASPN modulates key pathways involved in apoptosis, non-canonical autophagy, and metabolic reprogramming. Additionally, ASPN influenced immune response pathways and significantly affected TGF-{beta} signaling, a central mediator of cardiac fibrosis and remodeling post-MI. These findings indicate that ASPN plays a multifaceted role in regulating cellular responses to hypoxia and R/I. ConclusionsOur H/R model simulates key aspects of MI and R/I. The protective role of ASPN observed in this model suggests it as a promising candidate for developing cardioprotective therapies to minimize R/I and adverse cardiac-remodeling following MI.

physiology↗

bioRxiv2020

ADAR1 can drive Multiple Myeloma progression by acting both as an RNA editor of specific transcripts and as a DNA mutator of their cognate genes

RNA editing is an epitranscriptomic modification of emerging relevance to disease development and manifestations. ADAR1, which resides on human chromosome 1q21, is an RNA editor whose over-expression, either by interferon (IFN) induction or through gene amplification, is associated with increased editing and poor outcomes in Multiple Myeloma (MM). Here we explored the role of ADAR1 in the context of MM progression, by focusing on a group of 23 patients in the MMRF CoMMpass Study for which RNAseq and WES datasets exist for matched pre-and post-relapse samples. Our analysis reveals an acquisition of new DNA mutations on disease progression at specific loci surrounding the sites of ADAR associated (A-to-I) RNA editing. These analyses suggest that the RNA editing enzyme ADAR1 can function as a DNA mutator during Multiple Myeloma (MM) progression, and further imply that guide-targeted RNA editing has the capacity to generate specific mutational signatures at predetermined locations. This dual role of RNA editor and DNA mutator might be shared by other deaminases, such as APOBECs, so that DNA mutation might be the result of collateral damage on the genome by an editing enzyme whose primary job is to re-code the cognate transcript toward specific functional outcomes.

genomics↗